U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07222293) titled 'Assessment of AI Program 'DRISTi' as a Screening Tool' on Oct. 25.
Brief Summary: A study will be conducted to demonstrate that DRISTi will correctly diagnose Diabetic Retinopathy (e.g., mtmDR, PDR, DME) in eyes of patients with diabetes. Participants who have been diagnosed with diabetes mellitus and meet the other inclusion/exclusion criteria will be invited to participate and will consent to have ophthalmic images taken. These images will be analyzed by DRISTi AI software and evaluated by an ophthalmic reading center. The results will be compared, and a statistical analysis will be completed to ensure statistical significance in ...